During the past decade, Universitätsklinikum Leipzig, Klinik für Dermatologie, Venerologie und Allergologie conducted 5 clinical trials. In the 10-year time frame, 5 clinical trials started and 2 clinical trials were completed, i.e. on average, 40% percent of trials that started reached the finish line to date. In the past 5 years, 2 clinical trials started and 2 clinical trials were completed. i.e. 100% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Universitätsklinikum Leipzig, Klinik für Dermatologie, Venerologie und Allergologie" #1 sponsor was "Prof. Dr. med. Dirk Schadendorf" with 2 trials, followed by "Hoffmann-La Roche" with 1 trials sponsored, "LEO Pharma" with 1 trials sponsored, "Philogen S.p.A." with 1 trials sponsored and "University Hospital, Essen" with 1 trials sponsored. Other sponsors include -5 different institutions and companies that sponsored additional 5 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Universitätsklinikum Leipzig, Klinik für Dermatologie, Venerologie und Allergologie" #1 collaborator was "Bristol-Myers Squibb" with 1 trials as a collaborator. Other collaborators include -1 different institutions and companies that were collaborators in the rest 1 trials.

According to Clinical.Site data, the most researched conditions in "Universitätsklinikum Leipzig, Klinik für Dermatologie, Venerologie und Allergologie" are "Actinic Keratosis (AK)" (1 trials), "Advanced Solid Tumor" (1 trials), "Malignant Melanoma" (1 trials), "Malignant Melanoma Stage II" (1 trials) and "Melanoma" (1 trials). Many other conditions were trialed in "Universitätsklinikum Leipzig, Klinik für Dermatologie, Venerologie und Allergologie" in a lesser frequency.

Most popular intervention types in "Universitätsklinikum Leipzig, Klinik für Dermatologie, Venerologie und Allergologie" are "Drug" (6 trials). Other intervention types were less common.

The name of intervention was led by "Nivolumab" (2 trials), "Atezolizumab" (1 trials), "Atezolizumab Placebo" (1 trials), "Cobimetinib" (1 trials) and "Double Placebo Control" (1 trials). Other intervention names were less common.

The vast majority of trials in "Universitätsklinikum Leipzig, Klinik für Dermatologie, Venerologie und Allergologie" are 6 trials for "All" genders.

Currently, there are NaN active trials in "Universitätsklinikum Leipzig, Klinik für Dermatologie, Venerologie und Allergologie". undefined are not yet recruiting, 1 are recruiting, 3 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 2 completed trials in Universitätsklinikum Leipzig, Klinik für Dermatologie, Venerologie und Allergologie, undefined suspended trials, and undefined terminated clinical trials to date.

Out of the total trials that were conducted in Universitätsklinikum Leipzig, Klinik für Dermatologie, Venerologie und Allergologie, 1 "Phase 1" clinical trials were conducted, 2 "Phase 2" clinical trials and 2 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 1 trials, and there were also 0 trials that are defined as “Not Applicable".